Multi-center, Randomized, Double-blind, Active Controlled, Parallel Clinical Trial for the Evaluation of the Efficacy and Safety of CnU Cap. 750 mg in Patients With Cholesterol Gallstone
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 750 mg administration in patients with Cholesterol gallstone (radiolucent gallstones)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Individuals who have voluntarily agreed to participate in this clinical trial
• Adults aged 19 years and older
• Individuals diagnosed with gall bladder stone(GB stone) with a maximum diameter size of 15 mm or less, as determined by abdominal ultrasonography at the screening stage, and who have radiolucent GB stones on plain abdominal X-ray
Locations
Other Locations
Republic of Korea
Pusan National University Hospital
RECRUITING
Busan
CHA Bundang Medical Center
RECRUITING
Gyeonggi-do
Hallym University Dongtan Sacred Heart Hospital
RECRUITING
Gyeonggi-do
Soonchunhyang University Cheonan Hospital
RECRUITING
Gyeonggi-do
Inha University Hospital
RECRUITING
Incheon
Gangnam Severance Hospital
RECRUITING
Seoul
Time Frame
Start Date: 2025-07-28
Estimated Completion Date: 2026-06
Participants
Target number of participants: 484
Treatments
Experimental: CnU capsule 250 mg(1 capsule) and Ursa placebo tablet 200 mg(1 tablet)
Active_comparator: Ursa tablet 200 mg(1 tablet) and CnU placebo capsule 250 mg(1 capsule)
Related Therapeutic Areas
Sponsors
Leads: Myungmoon Pharma. Co. Ltd.